Ann Oncol 2022 Mar 23
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Abstract
Background
In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up of 27 months and key patient-reported outcomes (PROs) are presented.
Patients and methods
The safety population included all patients who received at least one dose of study treatment (n = 5591). Safety analyses included incidence, management, and outcomes of common and clinically relevant adverse events (AEs). Patient-reported health-related quality of life, ET symptoms, fatigue, and side-effect burden were assessed.
Results
The addition of abemaciclib to ET resulted in higher incidence of grade ≥3 AEs (49.7% versus 16.3% with ET alone), predominantly laboratory cytopenias [e.g. neutropenia (19.6%)] without clinical complications. Abemaciclib-treated patients experienced more serious AEs (15.2% versus 8.8%). Discontinuation of abemaciclib and/or ET due to AEs occurred in 18.5% of patients, mainly due to grade 1/2 AEs (66.8%). AEs were managed with comedications (e.g. antidiarrheals), abemaciclib dose holds (61.7%), and/or dose reductions (43.4%). Diarrhea was generally low grade (grade 1/2: 76%); grade 2/3 events were highest in the first month (20.5%), most were short-lived (≤7 days) and did not recur. Venous thromboembolic events (VTEs) were higher with abemaciclib + ET (2.5%) versus ET (0.6%); in the abemaciclib arm, increased VTE risk was observed with tamoxifen versus aromatase inhibitors (4.3% versus 1.8%). PROs were similar between arms, including being 'bothered by side-effects of treatment', except for diarrhea. At ≥3 months, most patients reporting diarrhea reported 'a little bit' or 'somewhat'.
Conclusions
In patients with high-risk EBC, adjuvant abemaciclib + ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile.
Related Questions
Do you provide prophylactic anticoagulation with abemaciclib in the adjuvant setting given known thrombosis risk?
I don’t generally recommend prophylactic anticoagulation with abema, either in the adjuvant or metastatic setting. There does appear to be a small, but real, incidence of thrombosis associated with abema, as well as the other CDK 4/6 inhibitors. While this risk is quite uncommon, it is important cer...
In the neoadjuvant setting, how would you treat a premenopausal woman with a 3 cm ER+, PR weakly positive, Her-2 negative, grade 3 breast cancer with clinical N1 node which shows basal type on Mammaprint?
This patient has high risk features and would likely benefit from chemotherapy. Given positive hormone expression (even if basal molecular type by Mammaprint), she would not be eligible for KEYNOTE-522 study. Hence, I would not recommend pembrolizumab. If there are no significant risks for complicat...
Does the magnitude of benefit with 2 years of adjuvant abemaciclib outweigh side effects, given that many patients will receive CDK 4/6 inhibitors at breast cancer recurrence, precluding OS benefits?
In terms of balancing benefit in terms of risk reduction of cancer recurrence versus adverse events, this is always an important consideration in introducing a novel therapy. In patients who are at high risk based on the criteria for the trial, namely node positive based on more than 4 nodes or if 1...
How far can you dose reduce abemaciclib for a patient who is having toxicity at starting doses?
I think this is an extremely important question with broad applicability to drug dosing in general, and particularly in the elderly who not uncommonly are both less tolerant and less forgiving of side effects. If drug efficacy is truly maintained over a range of dosing and not just dose related rela...
Will you offer adjuvant abemaciclib to breast cancer patients with high Ki-67 who are unable to receive either neoadjuvant or adjuvant chemotherapy due to comorbidities or who decline chemotherapy?
Chemotherapy was given to the majority of patients on MonarchE because they were high risk at diagnosis. For patients at high risk, I will continue to offer chemotherapy in addition to adding adjuvant abemaciclib to endocrine therapy. For those patients who refuse or in whom adjuvant chemotherapy is...